title: Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Ogata
authors.forename: Atsuyoshi
authors.initials: A
authors.lastname: Morishima
authors.forename: Toru
authors.initials: T
authors.lastname: Hirano
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Hishitani
authors.forename: Keisuke
authors.initials: K
authors.lastname: Hagihara
authors.forename: Yoshihito
authors.initials: Y
authors.lastname: Shima
authors.forename: Masashi
authors.initials: M
authors.lastname: Narazaki
authors.forename: Toshio
authors.initials: T
authors.lastname: Tanaka
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D005500:Follow-Up Studies; D006442:Glycated Hemoglobin / Q000378:metabolism*; D006801:Humans; D019947:Receptors, Interleukin-6 / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D006442:Glycated Hemoglobin; D019947:Receptors, Interleukin-6; C517652:hemoglobin A1c protein, human; C502936:tocilizumab